Georgetown university licenses use of tyrosine kinase inhibitors for treatment of neurodegenerative diseases
Georgetown University Medical Center News May 25, 2017
Georgetown University announced it has exclusively licensed worldwide intellectual property (IP) rights to develop and commercialize uses of tyrosine kinase (TK) inhibitors for the treatment of neurodegenerative diseases to Axovant Sciences GmbH. The application of TK inhibiting compounds for use in neurodegenerative diseases was discovered by a Georgetown University Medical Center (GUMC) researcher.
Georgetown holds an issued patent and several pending patent applications for the use of select TK inhibitors for the treatment of certain neurodegenerative diseases. Charbel Moussa, MBBS, PhD, scientific and clinical research director for GUMCÂs Translational Neurotherapeutics Program, is the named inventor on the IP.
ÂThe mechanism by which tyrosine kinase inhibitors affect neurodegenerative disorders appears to involve autophagy in the clearance of neurotoxic proteins associated with neurodegenerative diseases, explains Moussa, an assistant professor in GUMCÂs Department of Neurology.
Moussa collaborated with Fernando Pagan, MD, director of the Movement Disorders Program at MedStar Georgetown University Hospital who is the principal investigator on a phase II, randomized, double–blind, placebo–controlled clinical trial, which launched earlier this year to evaluate the safety and tolerability of low doses of nilotinib, a tyrosine kinase inhibitor, in ParkinsonÂs disease. A second study also was launched for AlzheimerÂs disease, on which R. Scott Turner, MD, PhD, director of GUMC Memory Disorders Program, is principal investigator.
ÂOur understanding of the autophagy process in neurodegenerative diseases represents the newest frontier of neurotherapeutic research and changes the paradigm on how we think about these diseases, Moussa says.
Go to Original
Georgetown holds an issued patent and several pending patent applications for the use of select TK inhibitors for the treatment of certain neurodegenerative diseases. Charbel Moussa, MBBS, PhD, scientific and clinical research director for GUMCÂs Translational Neurotherapeutics Program, is the named inventor on the IP.
ÂThe mechanism by which tyrosine kinase inhibitors affect neurodegenerative disorders appears to involve autophagy in the clearance of neurotoxic proteins associated with neurodegenerative diseases, explains Moussa, an assistant professor in GUMCÂs Department of Neurology.
Moussa collaborated with Fernando Pagan, MD, director of the Movement Disorders Program at MedStar Georgetown University Hospital who is the principal investigator on a phase II, randomized, double–blind, placebo–controlled clinical trial, which launched earlier this year to evaluate the safety and tolerability of low doses of nilotinib, a tyrosine kinase inhibitor, in ParkinsonÂs disease. A second study also was launched for AlzheimerÂs disease, on which R. Scott Turner, MD, PhD, director of GUMC Memory Disorders Program, is principal investigator.
ÂOur understanding of the autophagy process in neurodegenerative diseases represents the newest frontier of neurotherapeutic research and changes the paradigm on how we think about these diseases, Moussa says.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
